The ability to successfully translate basic research in leukemia to the clinical setting, as well as to better understand the relevance of observed clinical phenomena through laboratory-based research, is greatly facilitated by the availability of an extensive repository of tissue samples, with accompanying complete pathologic and clinical data, procured from leukemia patients. The OSUCCC Leukemia Tissue Bank Shared Resource (LTBSR), separate and distinct from the CALGB Leukemia Tissue Bank, is a shared resource established in 1997 with over 4,500 patient samples procured from 762 consented leukemia patients at OSU. The infrastructure of the OSUCCC LTBSR is well-established and is directly under our leadership. Specifically we have a large leukemia tissue repository, including both leukemic tissue and normal tissue germ line DNA, accompanied in all cases with complete pathologic, cytogenetic and clinical data for ready correlation of clinical and biological results. In addition, all the essentials of effective leukemia tissue bank management, including the activities of tissue collection, quality control of specimens, tissue storage, procurement of initial and follow-up samples and their pathology and clinical information, data entry and database management, and patient consent and confidentiality are very well developed. Furthermore, the procedures for prioritizing and distributing tissue to a large base of investigators within the OUCCC are effectively in place. Finally, our success in managing this large leukemia tissue resource can be seen in the documented sample collection for and sample distribution to all leukemia researchers within the CCC and 28 publications where the OSUCCC LTBSR has played a significant role. Against this background, we believe that this Shared Resource will function well in the support of the research mission of the OSUCCC in )roducing high-quality basic and clinical research in hematological malignancy. Currently the OSUCCC _TBSR is funded solely with OSUCCC/institutional support.
The Specific Aims of this Shared Resource are, therefore, to: 1) Continue to provide a central collection, processing and a state-of-the-art repository for samples collected from leukemia patients treated on OSU protocols, and 2) Provide materials from the LTBSR to interested investigators within OSUCCC, as well as to outside interested investigators involved in collaborative studies with OSU, who examine relevant cellular and molecular properties of leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-33
Application #
7630234
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
33
Fiscal Year
2008
Total Cost
$66,366
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Pan, Pan; Huang, Yi-Wen; Oshima, Kiyoko et al. (2018) An immunological perspective for preventing cancer with berries. J Berry Res 8:163-175

Showing the most recent 10 out of 2602 publications